1-877-936-8422

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

New dean of Basic Sciences aims to take Vanderbilt to the next level in biomedical research, drug discovery

Submitted by sobecksm on
Whether working on dynamic discoveries in the lab, connecting with students and faculty or pursuing his passion for nature photography, acclaimed biomedical researcher John Kuriyan is inspired by his recent move to join Vanderbilt as the new dean of the School of Medicine Basic Sciences and Distinguished University Professor.
https://news.vanderbilt.edu/2023/04/03/new-dean-of-basic-sciences-aims-to-take-vanderbilt-to-the-next-level-in-biomedical-research-drug-discovery/
Amy Wolf
Locked

Vulnerability found in immunotherapy-resistant triple-negative breast cancer

Submitted by robbikm2 on

Vanderbilt researchers have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.

https://news.vumc.org/2023/10/04/vulnerability-found-in-immunotherapy-resistant-triple-negative-breast-cancer/
Tom Wilemon
Locked

SPORE in Breast Cancer

SPORE in GI Cancer
Read More

Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

Miscellaneous

This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.
Miscellaneous
Early I
Osmundson, Evan
NCT05996432
VICC-EDMDT23195
Learn More

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

This is a single-arm, phase II study of patients with advanced liver cancer or hepatocellular carcinoma (HCC) who are eligible for first-line treatment with T300+D. The invesitgators hypothesize that T300+D will be safe and tolerated in CP-B patients with HCC. HCC mostly affects disadvantaged populations with higher rates among racial/ethnic minorities, who are often not included in clinical trials (i.e., Hispanics, Blacks, underserved, low socioeconomic status) and present with more severe disease. Given there is not much data in the US patient cohort, this study provides a chance to gain that knowledge.
Not Available
II
Not Available
NCT06526104
VICC-ITGIT23272
Learn More

High-Resolution PET-CT Imaging for Surgical Margin Visualization

Miscellaneous

Imaging will be exploratory and be used intraoperatively. There have been no discovered risks associated with the device to be used in this study, and none are anticipated given the diagnostic and non-invasive, 'ex vivo' nature of device use. Of note, the surgical resection will proceed as per standard of care and will not be affected by the research protocol.

Potential Benefit: Imaging intra-operatively will ensure surgeons to identify at risk resection margins.

Time Commitment: There are no additional visits that will be asked of you to partake in this study.

Drug is FDA approved and Exposure to Radiation is minimal.
Miscellaneous
I
Topf, Michael
NCT06915454
VICCHNP24616
Learn More

Clinical Trials Search CTA Inline Referral Form

To learn more about any of our clinical
trials, call 615-936-8422.

Call Now
NCI Designated Cancer Center
NCCN National Comprehensive Cancer Network
NCI National Clinical Trials Network